Spero therapeutics enters into a non-dilutive revenue interest financing agreement with healthcare royalty partners® for up to $125 million

Investment expected to extend spero therapeutics' cash runway into 2h 2023 investment expected to extend spero therapeutics' cash runway into 2h 2023
SPRO Ratings Summary
SPRO Quant Ranking